ParoxysmalNocturnalHemoglobinuria

CLINICAL NEWS | First Cohort of Patients Dosed In Phase 2 Study Of KP104 In PNH

KP104 is a first-in-class, bifunctional biologic designed to modulate complement activity through selective targeting of key intervention points in the alternative and terminal complement pathways. On July 28, 2022, the…